Atrial septal fenestration in children for treatment of end-stage pulmonary hypertension

Alain Fraisse, F. Paoli, V. Gressin, Zahid Amin, G. Simonneau, M. Humbert

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Patients and methods: Atrial septostomy was carried out in three children with end-stage pulmonary arterial hypertension and recurrent syncope. Continuous intravenous epoprostenol infusion was started concomitantly, in association with oral bosentan therapy. Results: Within a few weeks, the functional New York Heart Association (NYHA) class improved from III to II in all three patients. No recurrent syncope occurred and the children remained in NYHA functional class II during follow-up. The atrial septostomy remained patent and there was no need to increase the dose of intravenous epoprostenol. Conclusion: This small case series demonstrates that children with end-stage pulmonary arterial hypertension may benefit from an aggressive management, including fenestration of the atrial septum associated with the combination of bosentan and epoprostenol.

Original languageEnglish (US)
JournalCurrent Medical Research and Opinion
Volume23
Issue numberSUPPL. 2
DOIs
StatePublished - Aug 3 2007

Fingerprint

Epoprostenol
Pulmonary Hypertension
Syncope
Atrial Septum
Intravenous Infusions
Therapeutics
bosentan

Keywords

  • Atrial septostomy
  • Children
  • Interventional catheterisation
  • Paediatric PAH
  • Pulmonary arterial hypertension
  • Pulmonary vasodilators

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Atrial septal fenestration in children for treatment of end-stage pulmonary hypertension. / Fraisse, Alain; Paoli, F.; Gressin, V.; Amin, Zahid; Simonneau, G.; Humbert, M.

In: Current Medical Research and Opinion, Vol. 23, No. SUPPL. 2, 03.08.2007.

Research output: Contribution to journalArticle

Fraisse, Alain ; Paoli, F. ; Gressin, V. ; Amin, Zahid ; Simonneau, G. ; Humbert, M. / Atrial septal fenestration in children for treatment of end-stage pulmonary hypertension. In: Current Medical Research and Opinion. 2007 ; Vol. 23, No. SUPPL. 2.
@article{c9cace33a7d64a95bbcb8d36fbc6b90d,
title = "Atrial septal fenestration in children for treatment of end-stage pulmonary hypertension",
abstract = "Patients and methods: Atrial septostomy was carried out in three children with end-stage pulmonary arterial hypertension and recurrent syncope. Continuous intravenous epoprostenol infusion was started concomitantly, in association with oral bosentan therapy. Results: Within a few weeks, the functional New York Heart Association (NYHA) class improved from III to II in all three patients. No recurrent syncope occurred and the children remained in NYHA functional class II during follow-up. The atrial septostomy remained patent and there was no need to increase the dose of intravenous epoprostenol. Conclusion: This small case series demonstrates that children with end-stage pulmonary arterial hypertension may benefit from an aggressive management, including fenestration of the atrial septum associated with the combination of bosentan and epoprostenol.",
keywords = "Atrial septostomy, Children, Interventional catheterisation, Paediatric PAH, Pulmonary arterial hypertension, Pulmonary vasodilators",
author = "Alain Fraisse and F. Paoli and V. Gressin and Zahid Amin and G. Simonneau and M. Humbert",
year = "2007",
month = "8",
day = "3",
doi = "10.1185/030079907X199745",
language = "English (US)",
volume = "23",
journal = "Current Medical Research and Opinion",
issn = "0300-7995",
publisher = "Informa Healthcare",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Atrial septal fenestration in children for treatment of end-stage pulmonary hypertension

AU - Fraisse, Alain

AU - Paoli, F.

AU - Gressin, V.

AU - Amin, Zahid

AU - Simonneau, G.

AU - Humbert, M.

PY - 2007/8/3

Y1 - 2007/8/3

N2 - Patients and methods: Atrial septostomy was carried out in three children with end-stage pulmonary arterial hypertension and recurrent syncope. Continuous intravenous epoprostenol infusion was started concomitantly, in association with oral bosentan therapy. Results: Within a few weeks, the functional New York Heart Association (NYHA) class improved from III to II in all three patients. No recurrent syncope occurred and the children remained in NYHA functional class II during follow-up. The atrial septostomy remained patent and there was no need to increase the dose of intravenous epoprostenol. Conclusion: This small case series demonstrates that children with end-stage pulmonary arterial hypertension may benefit from an aggressive management, including fenestration of the atrial septum associated with the combination of bosentan and epoprostenol.

AB - Patients and methods: Atrial septostomy was carried out in three children with end-stage pulmonary arterial hypertension and recurrent syncope. Continuous intravenous epoprostenol infusion was started concomitantly, in association with oral bosentan therapy. Results: Within a few weeks, the functional New York Heart Association (NYHA) class improved from III to II in all three patients. No recurrent syncope occurred and the children remained in NYHA functional class II during follow-up. The atrial septostomy remained patent and there was no need to increase the dose of intravenous epoprostenol. Conclusion: This small case series demonstrates that children with end-stage pulmonary arterial hypertension may benefit from an aggressive management, including fenestration of the atrial septum associated with the combination of bosentan and epoprostenol.

KW - Atrial septostomy

KW - Children

KW - Interventional catheterisation

KW - Paediatric PAH

KW - Pulmonary arterial hypertension

KW - Pulmonary vasodilators

UR - http://www.scopus.com/inward/record.url?scp=34547442342&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547442342&partnerID=8YFLogxK

U2 - 10.1185/030079907X199745

DO - 10.1185/030079907X199745

M3 - Article

AN - SCOPUS:34547442342

VL - 23

JO - Current Medical Research and Opinion

JF - Current Medical Research and Opinion

SN - 0300-7995

IS - SUPPL. 2

ER -